Product Name:Bicalutamide

CAS:90357-06-5

MF:C18H14F4N2O4S

MW:430.37

EINECS:200-001-8

Bicalutamide was launched in the United Kingdom, its first worldwide market, for the treatment of advanced prostate cancer in combination with an LHRH analog or surgical castration. It was reportedly well tolerated with no significant cardiovascular and metabolic side effects due to the benefit of lacking any steroid activity. The efficacy of bicalutamide as a monotherapy has been demonstrated clinically. Promising response rates were also reported in treating colorectal, breast, pancreas and non-small cell lung cancers.

Function 

V1 taking anti-androgens drug. Prostate cancer therapeutic agents for the treatment of advanced prostate cancer.